What is the recommended initiation, dosing, titration, and contraindications for metoprolol in an adult patient?

Metoprolol: Initiation, Dosing, Titration, and Contraindications

For heart failure with reduced ejection fraction (HFrEF), initiate metoprolol succinate (extended-release) at 12.5-25 mg once daily and titrate every 1-2 weeks to a target dose of 200 mg daily; for acute myocardial infarction, give 5 mg IV every 5 minutes for 3 doses (total 15 mg), then 50 mg orally every 6 hours starting 15 minutes after the last IV dose, transitioning to 100 mg twice daily after 48 hours. 1, 2, 3

Clinical Context-Specific Dosing

Heart Failure with Reduced Ejection Fraction (HFrEF)

Only three beta-blockers reduce mortality in HFrEF: bisoprolol, carvedilol, and metoprolol succinate (extended-release). This is NOT a class effect—other beta-blockers should not be substituted. 2, 4

Initiation Protocol:

• Starting dose: Metoprolol succinate 12.5-25 mg once daily (use 12.5 mg for NYHA Class III-IV) 5, 6, 2
• Patient must be stable: No IV inotropes, minimal fluid retention, compensated state 5
• Titration schedule: Double the dose every 1-2 weeks as tolerated 5, 6
• Target dose: 200 mg once daily 5, 7, 2
• Maintenance: Continue indefinitely even if asymptomatic or LVEF improves 2

Critical dosing distinction: The target dose for HF (200 mg daily) is substantially higher than typical hypertension doses (25-100 mg daily). Medium-range doses do NOT provide equivalent mortality benefits to target doses. 7

Acute Myocardial Infarction (STEMI/NSTEMI)

IV Protocol (Early Treatment):

• Dose: 5 mg IV over 1-2 minutes, repeated every 5 minutes for total of 15 mg 1, 8, 3
• Timing: Initiate within first 24 hours after hemodynamic stabilization 1, 3
• Monitoring: Continuous ECG, frequent BP and heart rate checks during IV administration 8

Transition to Oral:

• If tolerates full IV dose: Start metoprolol tartrate 50 mg every 6 hours, beginning 15 minutes after last IV dose, continue for 48 hours 8, 3
• Maintenance: Transition to 100 mg twice daily after 48 hours 8
• If partial IV tolerance: Start 25 mg every 6 hours based on degree of intolerance 3
• Target heart rate: 50-60 bpm 8

Atrial Fibrillation (Rate Control)

IV bolus: 2.5-5 mg over 2 minutes, up to 3 doses 9
Oral maintenance: 25-200 mg twice daily 9

Hypertension

Starting dose: 25-100 mg daily (metoprolol tartrate) or 50-400 mg daily (metoprolol succinate) 10
Frequency: Tartrate requires twice-daily dosing; succinate allows once-daily 10

Absolute Contraindications

Do NOT administer metoprolol if ANY of the following are present: 1, 8, 3

• Heart rate <45-50 bpm (varies by indication: <45 for MI, <50 for UA/NSTEMI)
• Second- or third-degree AV block (without functioning pacemaker)
• Marked first-degree AV block (PR interval ≥0.24 seconds)
• Systolic BP <90-100 mm Hg (varies by indication)
• Cardiogenic shock or high risk for shock
• Decompensated heart failure (acute pulmonary edema, rales, S3 gallop)
• Severe reactive airway disease/active asthma
• History of angioedema with beta-blockers
• Hypersensitivity to metoprolol or related derivatives

Risk Factors for Cardiogenic Shock (Relative Contraindications)

The more factors present, the higher the risk: 1

• Age >70 years
• Systolic BP <120 mm Hg
• Sinus tachycardia >110 bpm OR heart rate <60 bpm
• Increased time since symptom onset
• Killip Class II or III

Special Populations & Cautions

Chronic Obstructive Pulmonary Disease (COPD):

• Use beta-1 selective agents (metoprolol) cautiously at reduced doses
• Start with 12.5 mg orally if mild wheezing or COPD history
• Consider short-acting formulation (tartrate) or esmolol initially to assess tolerance 8

Hepatic Impairment:

• Metoprolol levels increase substantially
• Initiate at low doses with cautious gradual titration 3

Renal Impairment:

• No dose adjustment required 3

Elderly (>65 years):

• Start with low doses due to decreased hepatic/cardiac function 3

Titration Management & Problem-Solving

Temporary worsening (20-30% of HF patients) may occur during titration: 6

If worsening symptoms/signs develop:

• Increasing congestion/edema: Double diuretic dose first; halve beta-blocker dose only if diuretics ineffective 5, 6
• Hypotension: Reduce vasodilator doses first; reduce beta-blocker if necessary 5
• Bradycardia: Reduce/discontinue other rate-lowering drugs; reduce beta-blocker only if necessary 5
• Marked fatigue: Consider halving beta-blocker dose (rarely necessary) 6

Always attempt reintroduction and uptitration once patient stabilizes. 5 In PARADIGM-HF, 40% of patients requiring temporary dose reduction were successfully restored to target doses. 7

Critical Clinical Pearls

Formulation matters: Metoprolol succinate (extended-release) was used in mortality trials for HF, NOT metoprolol tartrate (immediate-release). 4, 11 One trial showed carvedilol superior to metoprolol tartrate 50 mg twice daily, but this was neither the formulation nor dose proven effective in HF trials. 4

Abrupt withdrawal is dangerous: Can precipitate clinical deterioration; taper if discontinuation necessary. 2

Initiate early in HF: Beta-blockers should be started when HFrEF is diagnosed, including in-hospital after clinical stabilization, not delayed until symptoms worsen. 2

CYP2D6 polymorphisms: CYP2D6 poor metabolizers (5.7% of US population) have approximately 5-fold higher metoprolol exposure. 12 Consider lower starting doses if known poor metabolizer status.

Metoprolol-specific anti-inflammatory effects: Recent evidence suggests metoprolol (but not atenolol or propranolol) disrupts neutrophil dynamics during ischemia-reperfusion, providing unique cardioprotection beyond beta-blockade. 13 This supports metoprolol as the preferred IV beta-blocker for ongoing MI.